Attention :
*Although the info's are accurate at the time posted
might be out dated at the time you are reading .
You can reply with a suggetion or a correction.
Alert :
Info's provided for educational purposes only
and not as a substitute for professional medical advice, diagnosis or treatment.
Always consult your healthcare professional before any action related to this drug
« previous next »
Pages: [1]   Go Down

Author Topic: Droxidopa  (Read 139 times)

0 Members and 1 Guest are viewing this topic.

Offline Admin

  • Administrator
  • Administrator
  • *****
  • Posts: 715
  • Country: gr
  • Gender: Male
    • http://www.iasisnet.org
Droxidopa
« on: January 06, 2010, 07:46:14 pm »
 Generic Name : Droxidopa

Synonyms :

  • Droxydopa

  • L-DOPS

  • L-dihydroxyphenylserine

  • L-threo-3,4-dihydroxyphenylserine



Category :

  • Adrenergic alpha-Agonists

  • Sympathomimetics

  • Vasoconstrictor Agents



Description : Droxidopa is a precursor of noradrenaline that is used in the treatment of parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a deficit of noradrenaline as well as of dopamine in parkinson's disease and it has been proposed that this underlies the sudden transient freezing seen usually in advanced disease.

Indication : For treatment of neurogenic orthostatic hypotension associated with various disorders including Multiple System Atrophy, Familial Amyloid Polyneuropathy, hemodialysis induced hypotension and Parkinson's Disease. Also investigated for use/treatment in neurologic disorders, nephropathy, blood (blood forming organ disorders, unspecified), and dizzy/fainting spells.

State : Solid

Mechanism of Action : Droxidopa crosses the blood-brain barrier where it is converted to norepinephrine. Increased levels of norepinephrine in the central nervous system (CNS) may be beneficial to patients in a wide range of indications.

Synthesis Reference :

  • Balk SH, Yoshioka H, Yukawa H, Harayama S. Synthesis of L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS) with thermostabilized low-specific L-threonine aldolase from Streptomyces coelicolor A3(2). J Microbiol Biotechnol. 2007 May

  • 17(5):721-7.



Half Life : 2-3 hours

Dosage Form : TabletOral

Pharmacology : Droxidopa is an orally active synthetic precursor of norepinephrine that increases the deficient supply of norepinephrine in patients with NOH, thereby improving orthostatic blood pressure and alleviating associated symptoms of lightheadedness, dizziness, blurred vision, and syncope.

Brands : Dops

Brand Name Mixtures : N.A.
Logged
Pages: [1]   Go Up
« previous next »